Tesamorelin 5mg

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone studied in clinical and metabolic research for its effects on endogenous growth hormone signalling and body composition. Published literature has examined Tesamorelin most directly in the context of HIV-associated lipodystrophy, where it has been shown to reduce visceral adipose tissue and influence IGF-1 and metabolic markers in selected study populations (Stanley et al., 2011; Wang et al., 2009). As a peptide type, it is commonly explored in research involving endocrine regulation, fat metabolism, and growth hormone pulsatility. Supplied as a lyophilised peptide, this product is intended strictly for laboratory research use only. It is not approved for human consumption, and reported adverse effects in studied settings have included injection-site reactions, arthralgia, myalgia, fluid retention, and glucose-related changes (U.S. Food and Drug Administration, 2025).